Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study
Open Access
- 2 June 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 133 (12), 1397-1403
- https://doi.org/10.1097/cm9.0000000000000811
Abstract
Background Intensive therapy with disease modifying anti-rheumatic drugs (DMARDs) has been reported to improve the outcomes of rheumatoid arthritis (RA). However, real-world study on the effect of intensive therapy on RA sustained remission is still lacking. This study aimed to investigate the outcome of sustained intensive DMARD therapy (SUIT) for RA in a real-world 5-year consecutive cohort. Methods Based on a consecutive cohort of 610 out-patients with RA, remission of RA was assessed in 541 patients from 2012 to 2017, by dividing into SUIT, non-SUIT, and intermittent SUIT (Int-SUIT) groups. Changes in the disease activity scores were evaluated by 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR), 28-joint disease activity score based on C-reactive protein (DAS28-CRP), and clinical deep remission criteria (CliDR). Cumulative remission rates between different groups were compared using Kaplan-Meier curves and predictive factors of sustained remission were identified by univariate and multivariate logistic regression analysis. Results The remission rates of the SUIT group decreased from 12.0% (65/541) to 5.6% (20/359) based on DAS28-ESR, from 14.0% (76/541) to 7.2% (26/359) based on DAS28-CRP, and from 8.5% (46/541) to 3.1% (11/359) based on CliDR, respectively, with a gradually decreasing trend during the 5 years. The SUIT regimen led to a significantly higher cumulative remission rate than non-SUIT regimen based on DAS28-ESR (39.7%vs. 19.5%,P = 0.001), DAS28-CRP (42.0%vs. 19.6%,P = 0.001), and CliDR (24.5%vs. 8.7%,P = 0.001). The cumulative remission rates of patients treated with SUIT regimen were significantly higher than those treated with Int-SUIT regimen based on DAS28-ESR (39.7%vs. 25.7%,P = 0.043) and CliDR (24.5%vs. 14.2%,P = 0.047), but there was no significant difference between the two groups based on DAS28-CRP (42.0%vs. 27.4%,P = 0.066). Multivariate logistic regression analysis showed that the use of SUIT regimen was an independent favorable predictor according to different remission definitions (for DAS28-ESR: odds ratio [OR], 2.215, 95% confidence interval [CI]: 1.271-3.861,P = 0.005; for DAS28-CRP: OR, 1.520, 95% CI: 1.345-1.783,P = 0.002; for CliDR: OR, 1.525, 95% CI: 1.314-1.875,P = 0.013). Conclusion Sustained intensive treatment of RA is an optimal strategy in daily practice and will lead to an increased remission rate.Keywords
This publication has 16 references indexed in Scilit:
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid ArthritisArthritis & Rheumatology, 2015
- Tocilizumab in severe and refractory non-infectious uveitis.2014
- Therapies for Active Rheumatoid Arthritis after Methotrexate FailureThe New England Journal of Medicine, 2013
- Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessmentsAnnals Of The Rheumatic Diseases, 2011
- Evidence for predictive validity of remission on long‐term outcome in rheumatoid arthritis: A systematic reviewArthritis Care & Research, 2009
- Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?Annals Of The Rheumatic Diseases, 2005
- Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity statesArthritis & Rheumatism, 2005
- Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialThe Lancet, 2004
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995